Definitive Healthcare Corp

Definitive Healthcare Corp. engages in the provision of healthcare commercial intelligence. Its solution offers information on healthcare providers and their activities to help the customers optimize from product development to go-to-market planning, sales, and marketing execution. The company was founded by Jason Kranzt in February 2011 and is headquartered in Framingham, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Definitive Healthcare reports robust Q4 performance amidst industry challenges

Definitive Healthcare's Q4 2022 performance reflects strong revenue growth and profitability, driven by strategic acquisitions and product innovations, despite economic headwinds.
Challenges such as extended deal cycles and macroeconomic impacts require adaptive strategies, while opportunities in data matching, client growth, and market expansion offer avenues for future success.
The company's focus on cost management, sales enhancements, and long-term growth in the healthcare data market positions it well for sustained performance and industry leadership.
Guidance for Q1 2023 underscores financial stability and growth potential, signaling a proactive approach to navigating challenges and seizing opportunities in the evolving healthcare landscape.

Definitive Healthcare Corp reports solid Q1 results amidst growth strategies

Definitive Healthcare Corp (DH) delivered solid Q1 results amidst challenges, with a focus on enhancing data capabilities and strategic M&A for future growth.
While facing higher churn and margin impacts, the company remains resilient, with stable pricing and a proactive approach to driving performance improvements.
Opportunities lie in acquisitions, cross-selling to existing clients, and maintaining a strong market position through innovation and client value creation.

Definitive Healthcare reports strong Q2 earnings, eyes AI opportunities

Definitive Healthcare's Q2 performance showcased revenue growth, EBITDA margin, and strategic acquisitions, despite workforce reductions and customer declines.
The company's strengths lie in tech investments, market share gains, and cross-sell opportunities, while challenges include workforce reductions and economic uncertainties.
Opportunities in AI advancements, long-term market prospects, and strategic investments position Definitive Healthcare for sustained growth and client value creation.

Definitive Healthcare Corp excels in Q3 amidst market challenges

Definitive Healthcare Corp's Q3 showcased strong financial performance, customer wins, and a focus on innovation despite market challenges.
The company's resilience, marketing effectiveness, and strategies to address churn position it well for future growth and success.
With a commitment to product development, customer engagement, and market leadership, Definitive Healthcare Corp navigates tough market conditions with adaptability.

Definitive Healthcare posts solid Q4 results, eyes growth opportunities in 2024

Definitive Healthcare's Q4 2023 performance was strong, with revenue growth, margin maintenance, and client base expansion.
The company's strategic focus on product investments, customer retention, and innovation positions it well for growth in 2024.
Challenges in the life sciences segment and high M&A valuations are being addressed through strategic initiatives and market positioning.
Opportunities in data asset investment, margin growth, and strong demand present avenues for continued success and expansion.

Definitive Healthcare reports mixed Q1 results, eyes growth opportunities

Definitive Healthcare's Q1 2024 Earnings Call showcased a resilient performance amidst challenges, with a focus on operational excellence and product innovation. Despite facing macroeconomic headwinds and restructuring disruptions, the company remains optimistic about long-term opportunities, driven by improving macro conditions and strategic initiatives.

Definitive Healthcare reports Q2 revenue growth, addresses sales challenges

Definitive Healthcare's Q2 2024 earnings call highlighted mixed performance, with a focus on addressing sales challenges and enhancing operational efficiency. CEO Coop emphasized growth, profitability, and strategic changes to drive shareholder value.

Definitive Healthcare reports Q3 results, plans for growth and efficiency

Definitive Healthcare's Q3 performance showed resilience despite revenue and EBITDA declines, with a strategic focus on simplification and customer success.
While facing challenges like high churn rates, the company aims for future growth through new product offerings and customer expansion.
Opportunities lie in operational efficiency improvements, share buyback program expansion, and strategic product integration for enhanced value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Definitive Healthcare Corp. (NASDAQ:DH ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Matt Ruderman - Investor Relations Kevin Coop - Chief Executive Officer Richard Booth - Chief Financial Officer Conference Call Participants Jenny Shen - BTIG George Hill - Deutsche Bank Anna Kruszenski - Barclays Bank Operator Welcome to Definitive Healthcare's Q3 2024 Earnings Call. Later we will conduct a question-and-answer session.

Definitive Healthcare Corp. (DH)) Q3 2024 Earnings Call Transcript

Definitive Healthcare Corp. (DH) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.09 per share a year ago.

Definitive Healthcare Corp. (DH) Beats Q3 Earnings and Revenue Estimates

Third quarter revenue exceeded guidance, and the Company announced a $100 million repurchase authorization Third quarter revenue exceeded guidance, and the Company announced a $100 million repurchase authorization

Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2024

GE HealthCare Technologies Inc

Investors interested in Medical Info Systems stocks are likely familiar with Definitive Healthcare Corp. (DH) and GE HealthCare Technologies (GEHC). But which of these two stocks presents investors with the better value opportunity right now?

DH vs. GEHC: Which Stock Is the Better Value Option?

Monocl Conferences equips life science organizations with an intuitive solution to enhance conference planning and KOL engagement Monocl Conferences equips life science organizations with an intuitive solution to enhance conference planning and KOL engagement

Definitive Healthcare launches Monocl Conferences to improve conference planning and participation for biopharma and medtech organizations

Market Forecast equips providers with three, five, and 10-year market trend projections to strengthen strategic planning around future demand and growth opportunities Market Forecast equips providers with three, five, and 10-year market trend projections to strengthen strategic planning around future demand and growth opportunities

Definitive Healthcare launches predictive analytics solution that empowers healthcare organizations to prepare and plan for future market conditions

On September 30, 2024, Irenic Capital Management LP (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 6,413,185 shares of Definitive Healthcare Corp (DH, Financial). This transaction, executed at a price of $4.47 per share, marks a substantial increase in the firm's holdings in the healthcare sector, reflecting a strategic move to bolster its position in this industry.

Irenic Capital Management LP's Strategic Acquisition in Definitive Healthcare Corp

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (NASDAQ: DH) investors concerning the Company's possible violations of federal securities laws. On July 30, 2024, Definitive Healthcare disclosed that it took a $363.6 million goodwill impairment, and that as a result the Company was reducing its 2024 fiscal year guidance. On this news, Definitive Healthcare's stock price f.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Definitive Healthcare Corp. (DH) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (NASDAQ: DH) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Definitive Healthcare investments or would like to inquire about potentially pursuing claims to recover your l.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Definitive Healthcare Corp. (DH) on Behalf of Investors

FRAMINGHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Financial Officer, Rick Booth, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference.

Definitive Healthcare to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (NASDAQ: DH) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On July 30, 2024, Definitive Healthcare disclosed that it took a $363.6 million goodwill impairment, and that as a result the Company was reducing its 20.

The Law Offices of Frank R. Cruz Announces Investigation of Definitive Healthcare Corp. (DH) on Behalf of Investors

Population Intelligence empowers businesses to improve marketing campaigns and digital advertising performance with combined clinical and consumer insights Population Intelligence empowers businesses to improve marketing campaigns and digital advertising performance with combined clinical and consumer insights

Definitive Healthcare launches powerful consumer analytics and activation solution to more industries with Population Intelligence expansion

DH remains a hold rating due to its poor near-term outlook and recent results. 2Q24 results show decelerating growth, client count decline, and an elongated sales cycle. New CEO Kevin Coop could be a game changer, but there is no reason to invest in DH at this point.

Definitive Healthcare: Poor Near-Term Outlook, But New CEO May Change Things

Definitive Healthcare Corp. (NASDAQ:DH ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Matt Ruderman - Investor Relations Kevin Coop - Chief Executive Officer Rick Booth - Chief Financial Officer Conference Call Participants Saket Kalia - Barclays Craig Hettenbach - Morgan Stanley Joe Vruwink - Baird David Grossman - Stifel Matt Shea - Needham & Company Hanna Lee - Bank of America John McCary - Raymond James Jared Haase - William Blair Operator Welcome to Definitive Healthcare's Q2 2024 Earnings Call. At this time, all participants are in a listen-only mode.

Definitive Healthcare Corp. (DH) Q2 2024 Earnings Call Transcript

Definitive Healthcare Corp. (DH) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.08 per share a year ago.

Definitive Healthcare Corp. (DH) Meets Q2 Earnings Estimates

FRAMINGHAM, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June 30, 2024.

Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2024

FRAMINGHAM, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its second quarter ended June 30, 2024, on Monday, August 5, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

Definitive Healthcare Announces Timing of Its Second Quarter 2024 Financial Results Conference Call and Webcast

CHICAGO--(BUSINESS WIRE)--Leading advisory, tax and assurance firm Baker Tilly announces its collaboration with Definitive Healthcare to streamline fair market value (FMV) and key opinion leader (KOL) compliance procedures for life sciences companies. Leveraging Baker Tilly's decades of life sciences industry expertise and Definitive Healthcare's Monocl ExpertData, which facilitates the integration of expert data into internal systems and applications, this collaboration aims to set a new stand.

Baker Tilly and Definitive Healthcare enhance life sciences compliance

DH View Suite gives sales and marketing teams instant access to critical intelligence right from their mobile devices DH View Suite gives sales and marketing teams instant access to critical intelligence right from their mobile devices

Definitive Healthcare launches redesigned mobile app to enhance access to healthcare commercial intelligence

FRAMINGHAM, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that Definitive Healthcare's Board of Directors (the “Board”) granted inducement awards consisting of 1,137,038 performance-based restricted stock units (“PSUs”) and 1,170,047 time-based restricted stock units (“RSUs”) to Kevin Coop, Definitive Healthcare's new Chief Executive Officer and member of the Board, effective June 24, 2024. The awards were granted as an inducement material to Mr. Coop's commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).

Definitive Healthcare Corp. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Empowering healthcare and life science organizations with faster insights through seamless data sharing Empowering healthcare and life science organizations with faster insights through seamless data sharing

Definitive Healthcare Wins 2024 Databricks Healthcare and Life Sciences Partner of the Year Award

FRAMINGHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today released its 2023 sustainability report.

Definitive Healthcare Publishes 2023 Sustainability Report

FRAMINGHAM, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Founder, Interim CEO, and Executive Chairman, Jason Krantz, will present at the Stifel 2024 Cross Sector Insight Conference.

Definitive Healthcare to Present at the Stifel 2024 Cross Sector Insight Conference

Mr. Coop brings more than 30 years of Operations, Product and Revenue Expertise Mr. Coop brings more than 30 years of Operations, Product and Revenue Expertise

Definitive Healthcare Appoints Kevin Coop as CEO for Next Phase of Company's Growth

FRAMINGHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Founder, Interim CEO, and Executive Chairman, Jason Krantz, will present at the J.P. Morgan Global Technology, Media and Communications Conference.

News for Definitive Healthcare Corp Stock (DH)